Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.54 USD | +1.58% |
|
+2.85% | -2.45% |
Jul. 10 | Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:20 PM | |
Jul. 10 | AI Mania Masks Trade War Risks | ![]() |
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -26.42 | -20.26 | -27.08 | -14.04 | -10.73 | ||
Return on Total Capital | -29.12 | -22.54 | -30.34 | -14.94 | -11.52 | ||
Return On Equity % | -43.17 | -44.82 | -67.05 | 105.04 | -12.54 | ||
Return on Common Equity | -42.26 | -48.93 | -79.84 | 122.05 | -10.23 | ||
Margin Analysis | |||||||
Gross Profit Margin % | -3.41K | -748.5 | -778.5 | -314.52 | -1.78K | ||
SG&A Margin | 1.09K | 768.79 | 979.94 | 550.86 | 1.96K | ||
EBITDA Margin % | - | - | -1.73K | -847.72 | -3.69K | ||
EBITA Margin % | -4.5K | -1.52K | -1.75K | -857.66 | -3.74K | ||
EBIT Margin % | -4.5K | -1.52K | -1.76K | -865.37 | -3.74K | ||
Income From Continuing Operations Margin % | -3.78K | -1.67K | -2.01K | 3.39K | -2.51K | ||
Net Income Margin % | -3.4K | -1.53K | -1.65K | 3.48K | -591.96 | ||
Net Avail. For Common Margin % | -3.4K | -1.53K | -1.83K | 3.48K | -1.88K | ||
Normalized Net Income Margin | -2.53K | -730.62 | -984.47 | -433.2 | -1.14K | ||
Levered Free Cash Flow Margin | -2.38K | 56.05 | -975.56 | -421.44 | -1.29K | ||
Unlevered Free Cash Flow Margin | -2.37K | 64.01 | -947.04 | -404.02 | -1.29K | ||
Asset Turnover | |||||||
Asset Turnover | 0.01 | 0.02 | 0.02 | 0.03 | 0 | ||
Fixed Assets Turnover | 0.32 | 0.67 | 0.68 | 1.58 | 0.36 | ||
Receivables Turnover (Average Receivables) | 3.2 | - | 3.58 | 2.97 | - | ||
Inventory Turnover (Average Inventory) | - | - | - | 27.22 | - | ||
Short Term Liquidity | |||||||
Current Ratio | 9.99 | 11.64 | 6.6 | 25.24 | 33.47 | ||
Quick Ratio | 9.45 | 11.18 | 6.27 | 24.81 | 32.71 | ||
Operating Cash Flow to Current Liabilities | -2.52 | -3.68 | -3.1 | -2.87 | -5.62 | ||
Days Sales Outstanding (Average Receivables) | 114.21 | - | 102.02 | 123.07 | - | ||
Days Outstanding Inventory (Average Inventory) | - | - | - | 13.45 | - | ||
Average Days Payable Outstanding | 6.75 | 21.45 | - | 30.31 | 12.62 | ||
Cash Conversion Cycle (Average Days) | - | - | - | 106.21 | - | ||
Long Term Solvency | |||||||
Total Debt/Equity | 11.88 | 13.77 | 30.3 | 7.75 | 1.93 | ||
Total Debt / Total Capital | 10.62 | 12.1 | 23.25 | 7.19 | 1.89 | ||
LT Debt/Equity | 11.28 | 13.22 | 26.91 | 7.41 | 1.74 | ||
Long-Term Debt / Total Capital | 10.09 | 11.62 | 20.65 | 6.88 | 1.71 | ||
Total Liabilities / Total Assets | 20.38 | 20.26 | 32.73 | 10.72 | 4.59 | ||
EBIT / Interest Expense | -381.24 | -119.14 | -38.53 | -31.05 | - | ||
EBITDA / Interest Expense | -376.66 | -116.98 | -37.29 | -30.04 | - | ||
(EBITDA - Capex) / Interest Expense | -378.72 | -119.45 | -37.74 | -30.08 | - | ||
Total Debt / EBITDA | -0.23 | -0.34 | -0.47 | -0.48 | -0.09 | ||
Net Debt / EBITDA | 1.71 | 2.16 | 1.14 | 5.78 | 4.52 | ||
Total Debt / (EBITDA - Capex) | -0.23 | -0.34 | -0.46 | -0.48 | -0.09 | ||
Net Debt / (EBITDA - Capex) | 1.7 | 2.11 | 1.13 | 5.77 | 4.5 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | -64.85 | 132.34 | 10.84 | 103.65 | -11.19 | ||
Gross Profit, 1 Yr. Growth % | 312.4 | 92.57 | 15.28 | -17.73 | 29.48 | ||
EBITDA, 1 Yr. Growth % | - | - | 27.11 | -0.08 | 41.62 | ||
EBITA, 1 Yr. Growth % | 101.14 | 76.69 | 27.57 | 0.02 | 39.42 | ||
EBIT, 1 Yr. Growth % | 101.14 | 76.69 | 28.46 | 0.22 | 39.42 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 58.46 | 2.65 | 33.1 | -443.99 | -116.05 | ||
Net Income, 1 Yr. Growth % | -167.41 | 4.45 | 19.37 | -531 | -103.95 | ||
Normalized Net Income, 1 Yr. Growth % | 322.71 | 75.76 | 49.35 | -10.39 | 4.48 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | 80.73 | -1.74 | 25.19 | -431.01 | -113.39 | ||
Accounts Receivable, 1 Yr. Growth % | 205.86 | - | 683.37 | 76.26 | - | ||
Inventory, 1 Yr. Growth % | - | - | - | 1.18K | - | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.19 | 12.88 | 6.2 | -28.58 | 70.38 | ||
Total Assets, 1 Yr. Growth % | 4.55 | -0.18 | -7.56 | 202.25 | -24.72 | ||
Tangible Book Value, 1 Yr. Growth % | -11.53 | -7.83 | -38.87 | 475.66 | -21.46 | ||
Common Equity, 1 Yr. Growth % | -11.53 | -7.83 | -30.13 | 415.53 | -21.46 | ||
Cash From Operations, 1 Yr. Growth % | -27.23 | 22.75 | 24.44 | -9.26 | 9.69 | ||
Capital Expenditures, 1 Yr. Growth % | 18.1 | 200.31 | -27.22 | -89.11 | 232.78 | ||
Levered Free Cash Flow, 1 Yr. Growth % | 2.15K | -116.07 | -1.72K | -11.72 | 9 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | 2.67K | -118.52 | -1.5K | -12.81 | 9 | ||
Compound Annual Growth Rate Over Two Years | |||||||
Total Revenues, 2 Yr. CAGR % | 219.98 | -9.62 | 60.48 | 50.24 | -4.01 | ||
Gross Profit, 2 Yr. CAGR % | 2.07K | 45.06 | 49 | -2.61 | 10.16 | ||
EBITDA, 2 Yr. CAGR % | - | - | - | 12.7 | 16.51 | ||
EBITA, 2 Yr. CAGR % | 19.61 | 25.52 | 50.13 | 12.96 | 15.9 | ||
EBIT, 2 Yr. CAGR % | 19.61 | 25.52 | 50.65 | 13.46 | 15.9 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 5.44 | 27.54 | 16.89 | 113.98 | -9.4 | ||
Net Income, 2 Yr. CAGR % | -11.87 | -16.09 | 11.66 | 126.83 | -58.72 | ||
Normalized Net Income, 2 Yr. CAGR % | 48.04 | 68.36 | 62.02 | 15.69 | -8.15 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | 13.15 | -22.11 | 10.91 | 103.57 | -17.35 | ||
Accounts Receivable, 2 Yr. CAGR % | 162.39 | - | - | 271.58 | - | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 163.3 | 8.45 | 9.49 | -12.91 | 4.63 | ||
Total Assets, 2 Yr. CAGR % | 36.6 | 2.16 | -3.94 | 67.15 | 50.84 | ||
Tangible Book Value, 2 Yr. CAGR % | 58.35 | -9.7 | -24.94 | 87.59 | 115.13 | ||
Common Equity, 2 Yr. CAGR % | 58.35 | -9.7 | -19.75 | 89.79 | 101.22 | ||
Cash From Operations, 2 Yr. CAGR % | -26.55 | -5.49 | 23.59 | 6.26 | -0.23 | ||
Capital Expenditures, 2 Yr. CAGR % | -28.62 | 88.33 | 47.84 | -71.85 | -39.8 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 10.99 | 76.05 | 277.43 | -4.39 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 31.86 | 74.26 | 249.31 | -4.39 | ||
Compound Annual Growth Rate Over Three Years | |||||||
Total Revenues, 3 Yr. CAGR % | - | 187.6 | -3.26 | 73.74 | -19.3 | ||
Gross Profit, 3 Yr. CAGR % | - | 522.2 | 34.37 | 22.24 | 7.67 | ||
EBITDA, 3 Yr. CAGR % | - | - | - | - | 8.8 | ||
EBITA, 3 Yr. CAGR % | - | 3.87 | 26.2 | 31.12 | 9.01 | ||
EBIT, 3 Yr. CAGR % | - | 3.87 | 26.49 | 31.51 | 9.01 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 4.5 | 29.37 | 67.51 | -7.57 | ||
Net Income, 3 Yr. CAGR % | - | -6.74 | -5.63 | 75.16 | -41.18 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 13.69 | 61.77 | 32.99 | -6.54 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | -24.54 | -8.76 | 59.69 | -15.88 | ||
Accounts Receivable, 3 Yr. CAGR % | - | - | 102.31 | - | - | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 98.54 | 7.69 | -5.04 | 5.15 | ||
Total Assets, 3 Yr. CAGR % | - | 23.04 | -1.19 | 40.76 | 28.12 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 32.21 | -20.71 | 48.02 | 41.43 | ||
Common Equity, 3 Yr. CAGR % | - | 32.21 | -17.1 | 49.18 | 41.43 | ||
Cash From Operations, 3 Yr. CAGR % | - | -12.84 | 3.59 | 11.5 | 7.39 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 15.23 | 37.18 | -38.03 | -35.87 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 187.51 | 39.71 | 116.6 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 205.51 | 38.18 | 108.62 | ||
Compound Annual Growth Rate Over Five Years | |||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 121.82 | -15.56 | ||
Gross Profit, 5 Yr. CAGR % | - | - | - | 196.32 | 21.3 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 7.42 | 15.34 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 7.61 | 15.34 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 39.19 | 5.14 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 33.08 | -32.2 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | 14.48 | 18.27 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 12.24 | -18.43 | ||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 101.05 | - | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 42.79 | 6.45 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 39.08 | 17.03 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 52.07 | 18.19 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 52.78 | 18.19 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | -5.65 | 2.04 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | -34.42 | -1.32 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 71.68 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 79.11 |
- Stock Market
- Equities
- ROIV Stock
- Financials Roivant Sciences Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions